<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23558598</article-id><article-id pub-id-type="pmc">3659156</article-id><article-id pub-id-type="doi">10.12659/MSM.883870</article-id><article-id pub-id-type="publisher-id">883870</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>A &#x0201c;patient-tailored&#x0201d; treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krzesi&#x00144;ski</surname><given-names>Pawe&#x00142;</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-242">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-242">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-242">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-242">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-242">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-19-242">F</xref><xref ref-type="author-notes" rid="fn7-medscimonit-19-242">G</xref><xref ref-type="corresp" rid="c1-medscimonit-19-242"/></contrib><contrib contrib-type="author"><name><surname>Gielerak</surname><given-names>Grzegorz Gerard</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-242">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-242">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-242">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-242">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-242">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-19-242">F</xref></contrib><contrib contrib-type="author"><name><surname>Kowal</surname><given-names>Jaros&#x00142;aw J&#x000f3;zef</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-242">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-242">B</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-242">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-242">E</xref></contrib><aff id="af1-medscimonit-19-242">Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland</aff></contrib-group><author-notes><corresp id="c1-medscimonit-19-242">Corresponding Author: Pawe&#x00142; Krzesi&#x00144;ski, e-mail: <email>pkrzesinski@wim.mil.pl</email></corresp><fn id="fn1-medscimonit-19-242"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-19-242"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-19-242"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-19-242"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-19-242"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-19-242"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-19-242"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>05</day><month>4</month><year>2013</year></pub-date><volume>19</volume><fpage>242</fpage><lpage>250</lpage><history><date date-type="received"><day>08</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2013</copyright-statement><copyright-year>2013</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p></license></permissions><abstract><sec><title>Background</title><p>Arterial hypertension might be caused by hemodynamic disturbances such as fluid retention, increased vascular resistance, and hyperdynamic function of the heart. The aim of this study was to estimate the effectiveness of antihypertensive therapy based on hemodynamic assessment by impedance cardiography in a randomized, prospective, controlled trial.</p></sec><sec><title>Material/Methods</title><p>This study involved 128 patients (average age: 42.9&#x000b1;11.1 years) with arterial hypertension, randomized into groups: (1) empiric, and (2) hemodynamic, in which treatment choice considered impedance cardiography results. Evaluation of treatment effects was performed after 12 weeks and included office blood pressure measurement and ambulatory blood pressure monitoring.</p></sec><sec><title>Results</title><p>All final blood pressure values were lower in the hemodynamic group, significantly for office systolic blood pressure (empiric <italic>vs.</italic> hemodynamic: 136.1 <italic>vs.</italic> 131.6 mmHg; p=0.036) and diastolic blood pressure (87.0 <italic>vs.</italic> 83.7 mmHg; p=0.013), as well as night-time systolic blood pressure (121.3 <italic>vs.</italic> 117.2 mmHg; p=0.023) and diastolic blood pressure (71.9 <italic>vs.</italic> 68.4 mmHg; p=0.007). Therapy based on impedance cardiography significantly increased the reduction in office systolic blood pressure (11.0 <italic>vs.</italic> 17.3 mmHg; p=0.008) and diastolic blood pressure (7.7 <italic>vs.</italic> 12.2 mmHg; p=0.0008); as well as 24-h mean systolic blood pressure (9.8 <italic>vs.</italic> 14.2 mmHg; p=0.026), daytime systolic blood pressure (10.5 <italic>vs.</italic> 14.8 mmHg; p=0.040), and night-time systolic blood pressure (7.7 <italic>vs.</italic> 12.2 mmHg; p=0.032).</p></sec><sec><title>Conclusions</title><p>Antihypertensive treatment based on impedance cardiography can significantly increase blood pressure reduction in hypertensive patients.</p></sec></abstract><kwd-group><kwd>hypertension</kwd><kwd>blood pressure</kwd><kwd>impedance cardiography</kwd><kwd>cardiovascular diseases</kwd><kwd>antihypertensive agents</kwd><kwd>hemodynamics</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Arterial hypertension (AH) is an important clinical, social and economic problem. It is estimated to affect 1/4 of world&#x02019;s population [<xref ref-type="bibr" rid="b1-medscimonit-19-242">1</xref>]. AH is the main risk factor for ischaemic heart disease, heart failure, kidney failure and stroke. In the pathogenesis of hypertension, increased arterial tension is a result of complex mechanisms, and might be caused by fluid retention, increased vascular resistance, hyperdynamic function of the heart, etc. Current guidelines stress that antihypertensive therapy choice should be based on individual patient assessment [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>,<xref ref-type="bibr" rid="b3-medscimonit-19-242">3</xref>].</p><p>Impedance cardiography (ICG) is an easy technique for noninvasive hemodynamic monitoring of parameters that accurately characterize participation of these mechanisms in development of hypertension. It allows for assessment of cardiac index (CI), heart rate (HR), thoracic fluid content (TFC), and systemic vascular resistance index (SVRI) [<xref ref-type="bibr" rid="b4-medscimonit-19-242">4</xref>]. Clinical studies carried out so far demonstrated the effectiveness of ICG in individualization of antihypertensive treatment. According to Taler et al. [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>], ICG provides a better choice of medications and doses in terms of a patient&#x02019;s individual hemodynamic status. Smith et al. [<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>] also suggest that the use of ICG in hypertensive patients significantly improves treatment effectiveness and allows for monitoring therapy effects. However, there are no clear indications regarding therapy based on hemodynamic measurements and their criteria values, which significantly limits possibilities of using ICG in clinical practice.</p><p>The aim of this study was to estimate the effectiveness of a treatment algorithm based on hemodynamic parameters assessed by ICG in therapy of mild and moderate AH in a randomized, prospective, controlled trial.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="methods"><title>Study population</title><p>The study involved patients with at least 3-month history of mild or moderate AH defined according to European Society of Cardiology guidelines [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>]. The study was carried out in the Department of Cardiology and Internal Diseases, Military Institute of Medicine from March 2008 to June 2009.</p><p>Study inclusion criteria comprised: (1) not treated AH: increased blood pressure for at least 3 months and, (2) AH improperly controlled with 1 or 2 antihypertensive medicines. Exclusion criteria comprised: (1) confirmed secondary AH, (2) improperly controlled AH with 3 or more medicines, (3) heart failure, (4) cardiomyopathy, (5) significant heart rhythm disorders, (6) significant valvular disease, (7) kidney failure, (8) chronic obstructive pulmonary disease, (9) diabetes, (10) polyneuropathy, (11) peripheral vascular diseases, and (12) age &#x0003c;18 years and &#x0003e;65 years.</p><p>The study was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the Ethics Committee, Military Institute of Medicine (no 3/WIM/2008). Written informed consent was obtained from all patients prior to their inclusion into the study. The study was registered at <ext-link ext-link-type="uri" xlink:href="www.nauka-polska.pl">www.nauka-polska.pl</ext-link> (ID 227062).</p></sec><sec sec-type="methods"><title>Study design</title><p>The study was randomized (1:1), prospective, and simultaneously controlled by conventional treatment. Initial clinical evaluation was performed on the first visit. Patients who had been taking medicines before the study were advised to stop, and to take captopril sublingually in case of increased blood pressure.</p><p>On the second visit (after 2 weeks), all patients underwent the following examinations: interview and physical examination with office blood pressure measurement (OBPM), 24-h ambulatory blood pressure monitoring, ICG, electrocardiogram, echocardiography, and laboratory tests (ionogram, creatinine, fasting glucose, lipidogram).</p><p>After those examinations, the patients were divided into 2 groups according to previous randomization (with the use of RandomBots Medusa 2.0.2 software): (1) empiric group (GE), in which treatment choice was based on clinical data; and (2) hemodynamic group (HD), in which treatment choice was based on clinical data considering hemodynamic parameters established with ICG (<xref ref-type="fig" rid="f1-medscimonit-19-242">Figure 1</xref>). Treatment choice in both groups was made by independent researchers. Evaluation of treatment effects was performed by the researcher, blinded to assigned treatment on the third visit after 12 weeks, while carrying out control examinations, including office blood pressure, 24-h ambulatory blood pressure monitoring, and ICG.</p><p>Differences between the groups within blood pressure absolute values, blood pressure reduction and obtained blood pressure control after 12-week treatment were considered as final points (per protocol analysis).</p></sec><sec><title>Clinical examination</title><p>Clinical examination was performed during all the visits, with special consideration of history of cardiovascular risk factors and symptoms indicating secondary cause of AH, as well as organ damage. OBPM (Omron M4 Plus, Japan) was performed by technique compliant with European Society of Cardiology guidelines [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>].</p></sec><sec><title>Ambulatory blood pressure monitoring (ABPM)</title><p>All the patients included in the study underwent ABPM (Spacelabs 90207, Spacelabs, Medical Inc, Redmond, USA). Time from 6 a.m. to 10 p.m. was considered the daily activity period (daytime), with automatic blood pressure measurement in 10-minute intervals. During night rest (night-time: 10 p.m. &#x02013; 6 a.m.), the measurement was performed every 30 minutes. Test results were interpreted according to European Society of Cardiology guidelines [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>].</p></sec><sec><title>Impedance cardiography (ICG)</title><p>Measurement of hemodynamic parameters with ICG method was performed during a 10-minute examination at rest (Niccomo, Medis, Germany) in horizontal position in morning hours (7.30&#x02013;8.30). Blood pressure measurement was performed automatically every 2 minutes with an arm cuff. The other hemodynamic parameters were measured by the beat-to-beat method. The values of TFC, CI, SVRI, and HR from the 5<sup>th</sup> minute of the examination were taken into account in the treatment algorithm.</p><p>Cut-off values of SVRI, CI, HR, and TFC (from the 5<sup>th</sup> minute of the ICG examination) were as follows: (1) hyperconstrictive profile: in the case of SVRI &#x0003e;2500 dyn&#x000b7;s&#x000b7;cm<sup>&#x02212;5</sup>&#x000b7;m<sup>2</sup>, (2) hyperdynamic profile: as CI &#x0003e;4.2 l/min/m<sup>2</sup> and/or HR &#x0003e;80/min, (3) hypervolemic profile: as TFC &#x0003e;34 1/kOhm for men and &#x0003e;24 1/kOhm for women, and (4) balanced profile: as hemodynamic parameters below established threshold values.</p><p>The groups requiring combined therapy with regard to significantly increased blood pressure (mean blood pressure in the 24-h measurement period &#x0003e;140/90 mmHg) were also distinguished.</p></sec><sec><title>Echocardiography</title><p>To exclude any important heart abnormalities, echocardiography with the use of Vivid 7 apparatus (GE<italic>-</italic>Healthcare<italic>,</italic> the USA) was performed in the morning hours (7.30&#x02013;8.30) according to current Standards of Echocardiography Society of Polish Cardiac Society [<xref ref-type="bibr" rid="b7-medscimonit-19-242">7</xref>].</p></sec><sec><title>Treatment</title><p>Non-pharmacological treatment was administered according to current guidelines [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>]. Pharmacotherapy included drugs whose effectiveness in hypertension treatment had been confirmed in many clinical studies [<xref ref-type="bibr" rid="b8-medscimonit-19-242">8</xref>&#x02013;<xref ref-type="bibr" rid="b14-medscimonit-19-242">14</xref>]: lisinopril (ACEI, angiotensin-converting enzyme inhibitor), telmisartan (ARB, angiotensin receptor blocker), hydrochlorothiazide (thiazide diuretic), metoprolol (BB, beta-blocker), and amlodipine (CB, calcium blocker).</p><p>In the GE group the treatment was based on current guidelines. In monotherapy, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was preferred. In polytherapy, the second drug was: (1) thiazide diuretic in older patients, with isolated systolic hypertension, with features of fluid retention and intolerance of calcium blocker in the past; (2) CB in patients with metabolic syndrome; and (3) BB in younger patients and the occurrence of symptoms of increase sympathetic drive (e.g., tachycardia).</p><p>Treatment algorithm in HD group (<xref ref-type="fig" rid="f1-medscimonit-19-242">Figure 1</xref>) was arbitrarily determined. Absolute CI and SVRI values were established based on previous studies [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>,<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>,<xref ref-type="bibr" rid="b15-medscimonit-19-242">15</xref>,<xref ref-type="bibr" rid="b16-medscimonit-19-242">16</xref>]. TFC for both men and women were defined based on patients&#x02019; characteristics from clinical trials [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>,<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>], referring to the computational algorithm (sex-dependant) used in a Niccomo device. Taking into account the fact that increased HR had been reported to be unfavorable for prognosis [<xref ref-type="bibr" rid="b17-medscimonit-19-242">17</xref>&#x02013;<xref ref-type="bibr" rid="b20-medscimonit-19-242">20</xref>], HR &#x0003e;80/min at rest (from the 5<sup>th</sup> minute of the ICG examination) was considered as an additional indication to use beta-blocker.</p><p>In STEP 1, when the patient&#x02019;s hemodynamic profile was hyperdynamic &#x02013; BB was recommended; when hypervolemic &#x02013; thiazide diuretic; and when hyperconstrictive &#x02013; ACEI or ARB (if SVRI was &#x0003e;2800 dyn&#x000b7;s&#x000b7;cm<sup>&#x02013;5</sup>&#x000b7;m<sup>2</sup> &#x02013; ACEI/ARB with CB was recommended). In cases of complex hemodynamic disturbances, the combined therapy was used. STEP 2 was reserved for the patients with 24-h mean blood pressure &#x0003e;140/90 mmHg &#x02013; they were assumed to demand polytherapy and when ICG suggested only one hemodynamic disturbance (indication for the first drug) the second drug was added in combination as in <xref ref-type="fig" rid="f1-medscimonit-19-242">Figure 1</xref>.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>On the basis of the results of Smith et al. [<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>], the sample size for minimum change in office SBP reduction of 6 mmHg after 12 weeks of follow-up was calculated as 45 patients per treatment group (HD <italic>vs.</italic> GE, &#x003b1;-error 5%, statistical power 80%).</p><p>Statistical analysis of the obtained results was performed using Statistica 7.0 software (StatSoft Inc., USA). Normality of data distribution was checked by the Shapiro-Wilk test. All results are expressed as average values &#x000b1;SD for continuous variables and number of patients, as well as percentages for categorical variables. The groups and treatment effects were compared by the use of Student&#x02019;s t tests for normally distributed data, and non-parametric tests (Mann Whitney U test, chi<sup>2</sup> test/Fisher&#x02019;s exact test) for other than normally distributed data. P&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="methods"><title>Baseline clinical data</title><p>The study involved a group of 128 consecutive patients (91 men), average age 42.9&#x000b1;11.1 years (range: 19 to 65 years), with baseline characteristics presented in <xref ref-type="table" rid="t1-medscimonit-19-242">Table 1</xref>. The hemodynamic profiles in the study group were differentiated: increased SVRI was observed in 43.8% of patients, 25.8% of them were hypervolemic and 25.8% had hyperdynamic heart function. Almost 1/4 (22.0%) were characterized by balanced hemodynamic profile.</p></sec><sec><title>Treatment effects</title><p><xref ref-type="fig" rid="f2-medscimonit-19-242">Figure 2</xref> shows the protocol flowchart for a mean time of observation of 91.4&#x000b1;10.0 days. Fourteen patients were excluded from the final analysis because of meeting the exclusion criteria mentioned above.</p><p>Most commonly administered drugs in both groups were angiotensin-converting enzyme inhibitor (GE <italic>vs.</italic> HD: 54.6% <italic>vs.</italic> 47.5%, p=0.449), and angiotensin receptor blocker (34.6% <italic>vs.</italic> 37.3%, p=0.760). Polytherapy was less frequently administered in the GE group than in the HD group (48.3% <italic>vs.</italic> 66.1%, p=0.042). It was connected with more frequent use of beta-blocker (20.0% <italic>vs.</italic> 33.9%, p=0.096) and calcium blocker (9.1% <italic>vs.</italic> 23.7%, p=0.036) in the HD group, mostly in combined therapy. The use of diuretic was comparable (29.1% <italic>vs.</italic> 32.2%, p=0.719).</p><p>All final blood pressure values were lower in the HD group, significantly so for office blood pressure and night-time blood pressure. Analysis of change in average blood pressure values showed significantly greater blood pressure decrease in the HD group, especially in office blood pressure and average SBP values in ABPM (<xref ref-type="table" rid="t2-medscimonit-19-242">Table 2</xref>, <xref ref-type="fig" rid="f3-medscimonit-19-242">Figure 3</xref>). In HD group a higher percentage of patients with proper blood pressure control in office blood pressure and ABPM was observed. However, according to statistical assessment, significant differences occurred only for night-time DBP (such trend was also observed for other BP variables &#x02013; <xref ref-type="table" rid="t3-medscimonit-19-242">Table 3</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The discussion of antihypertensive treatment has lasted for many years, yet still no clear management algorithm has been found for antihypertensive pharmacotherapy. Therefore, according to the guidelines of world cardiac societies, management of hypertensive patients should focus on detailed diagnostics that allow individualization of treatment and evaluation of risk factors [<xref ref-type="bibr" rid="b2-medscimonit-19-242">2</xref>,<xref ref-type="bibr" rid="b3-medscimonit-19-242">3</xref>].</p><p>ICG is becoming an increasingly used tool for non-invasive hemodynamic monitoring. Its usefulness and accuracy in evaluation of the cardiovascular system in hypertensive patients results from a possibility of simultaneous evaluation of many hemodynamic parameters. Current guidelines, other researchers&#x02019; observations, and the authors&#x02019; own experiences in using ICG in antihypertensive treatment allowed for compilation of algorithm of antihypertensive treatment based on particular hemodynamic parameters. The methods of evaluating treatment effects allowed for objective assessment of the value of the suggested therapy.</p><sec sec-type="intro"><title>Characteristics of patient population</title><p>ICG assessment revealed significant variety in patients&#x02019; hemodynamic profiles. Signs of vasoconstriction were most common, while hypervolemia and hyperdynamic function of cardiac muscle were present in every fourth patient. The study population comprised young and middle-aged patients, which suggests the need for caution in extrapolation of the observations to other age groups. According to other researchers [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>,<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>,<xref ref-type="bibr" rid="b21-medscimonit-19-242">21</xref>,<xref ref-type="bibr" rid="b22-medscimonit-19-242">22</xref>], the percentage of disorders connected with hyperdynamic function of cardiac muscle among older people would be significantly lower, while the number of patients with signs of hyperconstriction and hypervolemia would rise.</p></sec><sec><title>Comparison of treatment effects</title><p>The effects of antihypertensive treatment were very good in both groups &#x02013; almost all average blood pressure values were within suggested norms. At the same time, it was observed that use of hemodynamic measurements increased effectiveness of antihypertensive therapy. Analysis of changes in blood pressure values revealed more strongly expressed antihypertensive effect in the HD group, both in office blood pressure and ABPM. Office blood pressure and ABPM pressure control were higher in the HD group. Although the differences were statistically significant only for night-time DBP, the 15% increase in percentage of patients with complete blood pressure control in ABPM seems to be clinically important.</p><p>When comparing these results to other researcher&#x02019;s observations, works by Smith et al. [<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>] and Taler et al. [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>] should be considered. In the CONTROL study [<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>], patients with no significant accompanying diseases, and with average blood pressure about 155/93 mmHg, underwent a 3-month therapy in which the HD group was modified based on comparing monthly ICG results (BioZ ICG Monitor, CardioDynamics). The authors considered normalization of CI (within 2.5&#x02013;4.2 l/min/m<sup>2</sup>) and SVRI (1680&#x02013;2580 dyn&#x000b7;s&#x000b7;cm<sup>&#x02013;5</sup>&#x000b7;m<sup>2</sup>) to be a substitute final product. Therapy based on hemodynamic evaluation was connected with significantly better blood pressure control, including a considerable decrease of average SBP and DBP values. The HD group had a higher percentage of subjects with blood pressure &#x0003c; 140/90 mmHg (77% <italic>vs.</italic> 57%; p&#x0003c;0.001), which is considered as the main final point. Good treatment effects in the HD group were more clearly expressed in this study, but its methods included 2 additional visits after the first and second month of therapy. Undoubtedly, it had a significant impact on treatment effects, as the therapy in the HD group was significantly modified during 3-months follow-up (frequency of withdrawals of initially chosen drug 0.8/treatment cycle, frequency of introducing a new drug 1.1/treatment cycle).</p><p>It is slightly more difficult to compare the obtained results to the work by Taler et al. [<xref ref-type="bibr" rid="b5-medscimonit-19-242">5</xref>], performed on a group of patients with resistant AH. Considerably higher initial blood pressure values (average 171/89 mmHg), older population (average age of 66 years), accompanying disorders (organ damage connected with AH &#x02013; 47%, type 2 diabetes &#x02013; 33%), and treatment with at least 2 drugs, suggest the need for caution in comparing these populations. During 3 months, the treatment was modified in the HD group almost 5 times. For justified reasons (resistant hypertension), the obtained average blood pressure values in office blood pressure were higher than in the other studies, but the antihypertensive effect was also more clearly expressed in the HD group within average blood pressure values (GE <italic>vs.</italic> HD: 147/79&#x000b1;2/1 <italic>vs.</italic> 139/72&#x000b1;1/1 mmHg; p&#x0003c;0.01) and control of blood pressure &#x0003c;140/90 mmHg (33% <italic>vs.</italic> 56%; p&#x0003c;0.05).</p><p>The considerable improvement in antihypertensive treatment effect in the HD group might be of great importance in terms of prognosis. According to Williams&#x02019; metanalysis of clinical studies [<xref ref-type="bibr" rid="b23-medscimonit-19-242">23</xref>], a decrease in blood pressure by 4/3 mmHg is connected with decrease in risk of stroke (by 23%), coronary disease (15%), and overall mortality (14%). In young hypertensive patients, permanent treatment optimalization should be related to significant improvement within primary prevention of cardiovascular disorders.</p></sec><sec><title>Administered treatment</title><p>HD patients were more frequently treated with more than 1 medication. However, significant differences applied to calcium blocker only used in polytherapy with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. It should be noticed that the most common polytherapy choice in the GE group was treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and thiazide diuretic, which resulted from clinical experience and knowledge based on results of high quality clinical studies and previous guidelines [<xref ref-type="bibr" rid="b24-medscimonit-19-242">24</xref>&#x02013;<xref ref-type="bibr" rid="b26-medscimonit-19-242">26</xref>]. In the HD group, the combination of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and calcium blocker was used with similar frequency, which agrees with current opinions in antihypertensive therapy formed in the ACCOMPLISH study [<xref ref-type="bibr" rid="b8-medscimonit-19-242">8</xref>]. The observed therapy trend in favour of vasodilators is similar to the CONTROL study, where drugs reducing SVRI were more frequently used in the HD group than in the GE group (92.8% <italic>vs.</italic> 80.0%) [<xref ref-type="bibr" rid="b6-medscimonit-19-242">6</xref>].</p><p>Observations of differences with greater frequency of administering polytherapy and number of used antihypertensive drugs require further comment. The detailed management algorithm in the HD group significantly limited subjectivity of the treatment choice. Concurrently, the treatment choice in the GE group was made by an experienced researcher and was based on his clinical experience and current guidelines. The therapeutic aim in both groups was to obtain proper blood pressure control, with simultaneous caution concerning overly aggressive blood pressure decrease in a short period time. Importantly, administration of a slightly greater amount of drugs (17.8%) resulted in improvement of blood pressure reduction by nearly 50% compared to the GE group, which proves the accuracy of the chosen antihypertensive therapy.</p></sec><sec sec-type="methods"><title>Study limitations</title><p>The obtained results should be applied with caution in women and in patients with significant chronic diseases (both were minorities in this study). The impossibility of blinding the physician choosing the therapy in the HD group made a potential bias. However, we tried to limit it by designing an algorithm based on criteria values and blinded evaluation of the treatment effect. Assessment of the long-term effect of therapy based on ICG would be also of significant value.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Impedance cardiography is a useful and easy method for evaluating patients with mild and moderate AH, which provides clinically important complementary data. Use of an antihypertensive treatment algorithm based on criteria values of particular hemodynamic parameters can significantly increase blood pressure reduction in hypertensive patients.</p></sec></body><back><fn-group><fn id="fn8-medscimonit-19-242"><p><bold>Source of support:</bold> The study was supported by the Military Institute of Medicine, Warsaw, Poland (study number 0000000148)</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-19-242"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Whelton</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name></person-group><article-title>Global burden of hypertension: analysis of worldwide data</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>217</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15652604</pub-id></element-citation></ref><ref id="b2-medscimonit-19-242"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><etal/></person-group><collab>ESH-ESC Task Force on the Management of Arterial Hypertension</collab><article-title>2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><fpage>1105</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">17563527</pub-id></element-citation></ref><ref id="b3-medscimonit-19-242"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Agabiti-Rosei</surname><given-names>E</given-names></name><etal/></person-group><article-title>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</article-title><source>Blood Press</source><year>2009</year><volume>18</volume><issue>6</issue><fpage>308</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">20001654</pub-id></element-citation></ref><ref id="b4-medscimonit-19-242"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>HO</given-names></name><name><surname>Taler</surname><given-names>SJ</given-names></name><name><surname>Strobeck</surname><given-names>JE</given-names></name></person-group><article-title>Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making</article-title><source>Am J Hypertens</source><year>2005</year><volume>18</volume><issue>2 Pt 2</issue><fpage>26S</fpage><lpage>43S</lpage><pub-id pub-id-type="pmid">15752931</pub-id></element-citation></ref><ref id="b5-medscimonit-19-242"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taler</surname><given-names>SJ</given-names></name><name><surname>Textor</surname><given-names>SC</given-names></name><name><surname>Augustine</surname><given-names>JE</given-names></name></person-group><article-title>Resistant hypertension: comparing hemodynamic management to specialist care</article-title><source>Hypertension</source><year>2002</year><volume>39</volume><issue>5</issue><fpage>982</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">12019280</pub-id></element-citation></ref><ref id="b6-medscimonit-19-242"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RD</given-names></name><name><surname>Levy</surname><given-names>P</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name></person-group><article-title>Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group: Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects (The CONTROL Trial)</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><fpage>769</fpage><lpage>75</lpage></element-citation></ref><ref id="b7-medscimonit-19-242"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasprzak</surname><given-names>JD</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>P&#x00142;o&#x00144;ska</surname><given-names>E</given-names></name><etal/></person-group><article-title>Echokardiografia w praktyce klinicznej &#x02013; Standardami Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego 2007</article-title><source>Kardiol Pol</source><year>2007</year><volume>65</volume><fpage>1142</fpage><lpage>62</lpage><comment>[in Polish]</comment><pub-id pub-id-type="pmid">18380065</pub-id></element-citation></ref><ref id="b8-medscimonit-19-242"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamerson</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group><collab>for the ACCOMPLISH trial investigators</collab><article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2417</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19052124</pub-id></element-citation></ref><ref id="b9-medscimonit-19-242"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Neldam</surname><given-names>S</given-names></name><name><surname>Tikkanen</surname><given-names>I</given-names></name><etal/></person-group><article-title>Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study</article-title><source>BMJ</source><year>2000</year><volume>321</volume><issue>7274</issue><fpage>1440</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11110735</pub-id></element-citation></ref><ref id="b10-medscimonit-19-242"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckett</surname><given-names>NS</given-names></name><name><surname>Peters</surname><given-names>R</given-names></name><name><surname>Fletcher</surname><given-names>AE</given-names></name><etal/></person-group><collab>HYVET Study Group</collab><article-title>Treatment of hypertension in patients 80 years of age or older</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1887</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">18378519</pub-id></element-citation></ref><ref id="b11-medscimonit-19-242"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>13</issue><fpage>1503</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11004140</pub-id></element-citation></ref><ref id="b12-medscimonit-19-242"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsalta</surname><given-names>D</given-names></name><name><surname>Anastasakis</surname><given-names>E</given-names></name><name><surname>Papadogiannis</surname><given-names>DE</given-names></name></person-group><article-title>Beta-blockers in the treatment of hypertension: latest data and opinions</article-title><source>Hellenic J Cardiol</source><year>2008</year><volume>49</volume><issue>1</issue><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18350781</pub-id></element-citation></ref><ref id="b13-medscimonit-19-242"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>F</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>1121</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18480116</pub-id></element-citation></ref><ref id="b14-medscimonit-19-242"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><etal/></person-group><collab>ONTARGET Investigators</collab><article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1547</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">18378520</pub-id></element-citation></ref><ref id="b15-medscimonit-19-242"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sramek</surname><given-names>BB</given-names></name><name><surname>Tichy</surname><given-names>JA</given-names></name><name><surname>Hojerova</surname><given-names>M</given-names></name><name><surname>Cervenka</surname><given-names>V</given-names></name></person-group><article-title>Normohemodynamic goal-oriented antihypertensive therapy improves the outcome</article-title><source>Am J Hypertens</source><year>1996</year><volume>9</volume><fpage>141A</fpage></element-citation></ref><ref id="b16-medscimonit-19-242"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flack</surname><given-names>JM</given-names></name></person-group><article-title>Noninvasive hemodynamic measurements: an important advance in individualizing drug therapies for hypertensive patients</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><issue>4</issue><fpage>646</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">16520406</pub-id></element-citation></ref><ref id="b17-medscimonit-19-242"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palatini</surname><given-names>P</given-names></name></person-group><article-title>Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms</article-title><source>Drugs</source><year>2007</year><volume>67</volume><issue>Suppl 2</issue><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17999559</pub-id></element-citation></ref><ref id="b18-medscimonit-19-242"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palatini</surname><given-names>P</given-names></name><name><surname>Dorigatti</surname><given-names>F</given-names></name><name><surname>Zaetta</surname><given-names>V</given-names></name><etal/></person-group><collab>HARVEST Study Group</collab><article-title>Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study</article-title><source>J Hypertens</source><year>2006</year><volume>24</volume><issue>9</issue><fpage>1873</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16915038</pub-id></element-citation></ref><ref id="b19-medscimonit-19-242"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>A</given-names></name><name><surname>Bourassa</surname><given-names>MG</given-names></name><name><surname>Guertin</surname><given-names>MC</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name></person-group><article-title>Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>10</issue><fpage>967</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15774493</pub-id></element-citation></ref><ref id="b20-medscimonit-19-242"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piwo&#x00144;ska</surname><given-names>A</given-names></name><name><surname>Piotrowski</surname><given-names>W</given-names></name><name><surname>Broda</surname><given-names>G</given-names></name><etal/></person-group><article-title>The relationship between resting heart rate and atherosclerosis risk factors</article-title><source>Kardiol Pol</source><year>2008</year><volume>66</volume><issue>10</issue><fpage>1069</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">19006028</pub-id></element-citation></ref><ref id="b21-medscimonit-19-242"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Protogerou</surname><given-names>AD</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name><name><surname>Iaria</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diastolic blood pressure and mortality in the elderly with cardiovascular disease</article-title><source>Hypertension</source><year>2007</year><volume>50</volume><issue>1</issue><fpage>172</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17515449</pub-id></element-citation></ref><ref id="b22-medscimonit-19-242"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeglin</surname><given-names>MA</given-names></name><name><surname>Pacos</surname><given-names>J</given-names></name><name><surname>Bisognano</surname><given-names>JD</given-names></name></person-group><article-title>Hypertension in the very elderly: Brief review of management</article-title><source>Cardiol J</source><year>2009</year><volume>16</volume><issue>4</issue><fpage>379</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19653187</pub-id></element-citation></ref><ref id="b23-medscimonit-19-242"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name></person-group><article-title>Recent hypertension trials: implications and controversies</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>6</issue><fpage>813</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15766813</pub-id></element-citation></ref><ref id="b24-medscimonit-19-242"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><etal/></person-group><collab>National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee</collab><article-title>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>19</issue><fpage>2560</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12748199</pub-id></element-citation></ref><ref id="b25-medscimonit-19-242"><label>25</label><element-citation publication-type="journal"><collab>PROGRESS Collaborative Group</collab><article-title>Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9287</issue><fpage>1033</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11589932</pub-id></element-citation></ref><ref id="b26-medscimonit-19-242"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shikata</surname><given-names>C</given-names></name><name><surname>Sekikawa</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>N</given-names></name><etal/></person-group><article-title>Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension</article-title><source>Exp Clin Cardiol</source><year>2007</year><volume>12</volume><issue>1</issue><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18650977</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-19-242" position="float"><label>Figure 1</label><caption><p>Treatment algorithm based of particular hemodynamic parameters. ACEI &#x02013; angiotensin converting enzyme inhibitor, ARB &#x02013; angiotensin receptor blocker, BP &#x02013; blood pressure, CB &#x02013; calcium blocker, CI &#x02013; cardiac index, HR &#x02013; heart rate, SVRI &#x02013; systemic vascular resistance index, TFC &#x02013; thoracic fluid content.</p></caption><graphic xlink:href="medscimonit-19-242-g001"/></fig><fig id="f2-medscimonit-19-242" position="float"><label>Figure 2</label><caption><p>The protocol flowchart.</p></caption><graphic xlink:href="medscimonit-19-242-g002"/></fig><fig id="f3-medscimonit-19-242" position="float"><label>Figure 3</label><caption><p>Treatment effect within BP change (p value in italic).</p></caption><graphic xlink:href="medscimonit-19-242-g003"/></fig><table-wrap id="t1-medscimonit-19-242" position="float"><label>Table 1</label><caption><p>Basic characteristics.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">GE (n=63)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HD (n=65)</th><th align="center" valign="bottom" rowspan="1" colspan="1">p</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study group (n=128)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Men, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (74.6)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (67.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.389</td><td align="center" valign="top" rowspan="1" colspan="1">91 (71.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years), mean &#x000b1;SD</td><td align="center" valign="top" rowspan="1" colspan="1">42.6&#x000b1;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">43.2&#x000b1;11.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.869</td><td align="center" valign="top" rowspan="1" colspan="1">42.9&#x000b1;11.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m2), mean &#x000b1;SD</td><td align="center" valign="top" rowspan="1" colspan="1">28.5&#x000b1;4.7</td><td align="center" valign="top" rowspan="1" colspan="1">28.6&#x000b1;3.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.744</td><td align="center" valign="top" rowspan="1" colspan="1">28.6&#x000b1;4.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg), mean &#x000b1;SD</td><td align="center" valign="top" rowspan="1" colspan="1">147.9&#x000b1;9.7</td><td align="center" valign="top" rowspan="1" colspan="1">148.4&#x000b1;13.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.858</td><td align="center" valign="top" rowspan="1" colspan="1">148.2&#x000b1;11.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg), mean &#x000b1;SD</td><td align="center" valign="top" rowspan="1" colspan="1">95.4&#x000b1;8.4</td><td align="center" valign="top" rowspan="1" colspan="1">95.7&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.324</td><td align="center" valign="top" rowspan="1" colspan="1">95.6&#x000b1;8.3</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Nicotinism</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Presently, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (25.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (21.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.606</td><td align="center" valign="top" rowspan="1" colspan="1">30 (23.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">In the past, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (30.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.786</td><td align="center" valign="top" rowspan="1" colspan="1">38 (29.7)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Treatment before recruitment</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (30.2)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (23.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.364</td><td align="center" valign="top" rowspan="1" colspan="1">34 (26.6)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Family history</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AH, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (46.0)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (53.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.376</td><td align="center" valign="top" rowspan="1" colspan="1">64 (50.0)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Symptoms</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Headaches, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (42.9)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (52.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.285</td><td align="center" valign="top" rowspan="1" colspan="1">61 (47.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Malaise, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (31.8)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (30.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.905</td><td align="center" valign="top" rowspan="1" colspan="1">40 (31.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dizziness, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (11.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.076</td><td align="center" valign="top" rowspan="1" colspan="1">9 (7.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vision disorders, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.964</td><td align="center" valign="top" rowspan="1" colspan="1">8 (6.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Asymptomatic, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (39.7)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (35.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.616</td><td align="center" valign="top" rowspan="1" colspan="1">48 (37.5)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Concomitant diseases</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="top" rowspan="1" colspan="1">43 (68.3)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (72.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.616</td><td align="center" valign="top" rowspan="1" colspan="1">90 (70.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metabolic syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">32 (50.8)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (61.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.221</td><td align="center" valign="top" rowspan="1" colspan="1">72 (56.3)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-19-242"><p>AH &#x02013; arterial hypertension; BMI &#x02013; body mass index; DBP &#x02013; diastolic blood pressure; IHD &#x02013; ischaemic heart disease; SBP &#x02013; systolic blood pressure; SD &#x02013; standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-medscimonit-19-242" position="float"><label>Table 2</label><caption><p>Treatment effect within BP and hemodynamic parameters.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">GE (n=55)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HD (n=59)</th><th align="center" valign="bottom" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>OBPM, mean &#x000b1;SD</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">147.1&#x000b1;9.5</td><td align="center" valign="top" rowspan="1" colspan="1">148.9&#x000b1;13.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.428</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">136.1&#x000b1;12.0</td><td align="center" valign="top" rowspan="1" colspan="1">131.6&#x000b1;11.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">94.8&#x000b1;7.8</td><td align="center" valign="top" rowspan="1" colspan="1">95.9&#x000b1;8.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.422</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">87.0&#x000b1;7.1</td><td align="center" valign="top" rowspan="1" colspan="1">83.7&#x000b1;6.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>ABPM, mean &#x000b1;SD</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24-h mean SBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">140.0&#x000b1;10.1</td><td align="center" valign="top" rowspan="1" colspan="1">141.8&#x000b1;10.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.302</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24-h mean SBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">130.2&#x000b1;9.4</td><td align="center" valign="top" rowspan="1" colspan="1">127.7&#x000b1;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24-h mean DBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">88.2&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">88.1&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.967</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24-h mean DBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">79.7&#x000b1;7.8</td><td align="center" valign="top" rowspan="1" colspan="1">78.0&#x000b1;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Daytime SBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">144.3&#x000b1;10.3</td><td align="center" valign="top" rowspan="1" colspan="1">147.0&#x000b1;10.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Daytime SBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">133.8&#x000b1;10.1</td><td align="center" valign="top" rowspan="1" colspan="1">132.2&#x000b1;8.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.368</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Daytime DBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">91.7&#x000b1;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">92.3&#x000b1;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.704</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Daytime DBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">82.6&#x000b1;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">81.6&#x000b1;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.408</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Night-time SBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">129.0&#x000b1;10.9</td><td align="center" valign="top" rowspan="1" colspan="1">129.4&#x000b1;12.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.871</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Night-time SBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">121.3&#x000b1;9.5</td><td align="center" valign="top" rowspan="1" colspan="1">117.2&#x000b1;9.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Night-time DBP (mmHg), baseline</td><td align="center" valign="top" rowspan="1" colspan="1">78.8&#x000b1;8.9</td><td align="center" valign="top" rowspan="1" colspan="1">77.9&#x000b1;8.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.565</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Night-time DBP (mmHg), after 12 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">71.9&#x000b1;7.2</td><td align="center" valign="top" rowspan="1" colspan="1">68.4&#x000b1;6.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-medscimonit-19-242"><p>ABPM &#x02013; ambulatory blood pressure monitoring; DBP &#x02013; diastolic blood pressure; OBPM &#x02013; office blood pressure measurement; SBP &#x02013; systolic blood pressure; SD &#x02013; standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-19-242" position="float"><label>Table 3</label><caption><p>Treatment effect within BP control.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">GE (n=55)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HD (n=59)</th><th align="center" valign="bottom" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">OBPM &#x0003c; 140/90 mmHg, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (45.5)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (61.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.096</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABPM<xref ref-type="table-fn" rid="tfn3-medscimonit-19-242">*</xref>, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (25.4)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;24-h mean SBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (52.7)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (67.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;24-h mean DBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (71.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Daytime SBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (66.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.207</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Daytime DBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (58.2)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (72.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Night-time SBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (47.3)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (64.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Night-time DBP (mmHg), n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (43.6)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (64.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-medscimonit-19-242"><label>*</label><p>24-h mean BP &#x0003c;130/80 mmHg and daytime BP &#x0003c;135/85 mmHg and night-time BP &#x0003c;120/70 mmHg.</p></fn><fn id="tfn4-medscimonit-19-242"><p>ABPM &#x02013; ambulatory blood pressure monitoring; DBP &#x02013; diastolic blood pressure; OBPM &#x02013; office blood pressure measurement; SBP &#x02013; systolic blood pressure.</p></fn></table-wrap-foot></table-wrap></floats-group></article>